Paul Monaco, MD
Internal Medicine · Hamden, CTNPI 1366436537
Payments from drug & device makers
Across 145 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$336
- Johnson & Johnson$292
- GSK$289
- Lilly USA, LLC$275
- Amgen$247
- Amarin Pharma, Inc.$226
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$231%
- Food & beverage$2,92499%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $336 |
| Johnson & Johnson(2 entities) | 13 | $292 |
| GSK | 10 | $289 |
| Lilly USA, LLC | 15 | $275 |
| Amgen | 11 | $247 |
| Amarin Pharma, Inc. | 14 | $226 |
| Pfizer | 10 | $171 |
| E.r. Squibb & Sons, L.L.C. | 5 | $112 |
| AbbVie(2 entities) | 5 | $109 |
| Sunovion Pharmaceuticals Inc. | 4 | $77 |
| AstraZeneca | 5 | $77 |
| Merck | 4 | $73 |
| Eisai Inc. | 4 | $70 |
| Astellas Pharma US Inc | 4 | $69 |
| Endo Pharmaceuticals Inc. | 4 | $67 |
| ANI Pharmaceuticals, Inc. | 2 | $56 |
| Boehringer Ingelheim | 3 | $55 |
| Scilex Pharmaceuticals Inc. | 1 | $53 |
| Avanir Pharmaceuticals, Inc. | 2 | $48 |
| Ultragenyx Pharmaceutical Inc. | 2 | $32 |
| Novartis | 2 | $30 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Boston Scientific | 1 | $25 |
| Acorda Therapeutics, Inc | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Seqirus USA Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$108
How this compares
$2,947 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 467 | $171,198 |
| OzempicSemaglutide | 85 | $81,689 |
| JardianceEmpagliflozin | 103 | $71,575 |
| XifaxanRifaximin | 35 | $70,267 |
| XareltoRivaroxaban | 126 | $61,317 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $48,958 |
| TrulicityDulaglutide | 36 | $34,536 |
| FarxigaDapagliflozin Propanediol | 70 | $34,368 |
| JanuviaSitagliptin Phosphate | 62 | $33,619 |
| TradjentaLinagliptin | 68 | $23,033 |
| MyrbetriqMirabegron | 64 | $22,543 |
| LinzessLinaclotide | 25 | $18,157 |
| MounjaroTirzepatide | 17 | $17,018 |
| Spiriva RespimatTiotropium Bromide | 22 | $11,878 |
| Atorvastatin Calcium | 810 | $11,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $171 | $171,198467 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $55 | $106,487193 claims |
| Novo NordiskOzempic | $336 | $81,68985 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $289 | $65,967112 claims |
| Johnson & JohnsonXarelto | $292 | $61,317126 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $275 | $56,398174 claims |
| AstraZenecaFarxiga, Symbicort | $77 | $39,26491 claims |
| MerckJanuvia | $73 | $33,61962 claims |
| Astellas Pharma US IncMyrbetriq | $69 | $22,54364 claims |
| AbbVieLinzess, Lumigan | $109 | $22,46341 claims |
| NovartisEntresto | $30 | $7,50622 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $5,498418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in Hamden
- Margaret ChusteckaHamden$652K
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.